Week in Review: Hisun and Ambrx Team Up to Develop Cancer Drugs

Zhejiang Hisun Pharma will collaborate with Ambrx of San Diego to develop bispecific cancer treatments in China; Pfizer's attempt to acquire AstraZeneca could face anti-trust problems in China because the companies are the two largest multinational pharmas in China; Sinovac Biotech licensed rights to a polio vaccine from Intravacc of the Netherlands; Hutchison MediPharma has begun a double-blind China Phase II trial of its Lilly-partnered colorectal cancer treatment; TaiGen Biotech of Taiwan said the CFDA review of its novel antibiotic is expected soon; WuXi PharmaTech has broken ground on a new facility to manufacture cell therapies in Philadelphia; and Concord Medical will build a 400-bed cancer specialty hospital in the Shanghai New Hongqiao International Medical Center. More details…. Stock Symbols: (SHA: 600267) (NYSE: PFE) (NYSE: AZN) (NSDQ: SVA) (NYSE: LLY) (TWO: 4157) (NYSE: WX) (NYSE: CCM) Share this with colleagues: // //